Inicio › Mieloma múltiple › California

Ensayos clínicos de Mieloma múltiple en California

68 estudios sobre Mieloma múltiple buscan participantes en California.

Ciudades en California

Texto oficial del estudio (inglés)

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Beverly Hills Cancer Center, Beverly Hills
Clovis Community Medical Center, Clovis
Community Cancer Institute, Clovis
y 9 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT06152575

Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

City of Hope National Medical Center, Duarte
City of Hope - Lennar Foundation Cancer Center, Irvine

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT07555938

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Scripps Clinic Torrey Pines, La Jolla

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT05137054

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

City of Hope, Duarte

ReclutandoEstudio observacionalSe aceptan voluntarios sanos

Edades de 40 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT05366881

A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

Beverly Hills Cancer Center (BHCC), Beverly Hills
City of Hope Orange County Lennar Foundation Cancer Center, Irvine
Stanford University Medical Center, Palo Alto

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT07589634

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

City of Hope, Duarte
University of California San Francisco, San Francisco
Stanford University Medical Center, Stanford

ReclutandoFase 4

Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT05201781

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

University of California San Francisco, San Francisco

ReclutandoFase 2

Edades de 18 a 80 · Todos los sexos · Actualizado el 3 nov 2026 · NCT07149857

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

UCSF Fresno, Clovis
City of Hope Duarte, Duarte
City of Hope Orange County Lennar Foundation Cancer Center, Irvine
y 2 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT05552222

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

City of Hope, Duarte
City of Hope Orange County Lennar Foundation Cancer Center, Irvine
University of California San Francisco, San Francisco

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT05652335

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

City of Hope Duarte, Duarte
City of Hope Orange County Lennar Foundation Cancer Center, Irvine
USC Norris Comprehensive Cancer Center, Los Angeles
y 2 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT07258511

Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma

City of Hope Medical Center, Duarte

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 oct 2026 · NCT05363111

Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma

UC San Diego Moores Cancer Center, La Jolla
Stanford Cancer Institute, Stanford

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 oct 2026 · NCT06433947

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

City of Hope, Duarte
Berenson Cancer Center, West Hollywood

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 oct 2026 · NCT07284758

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

UC Davis Comprehensive Cancer Center, Sacramento
UCLA Health, Jonsson Comprehensive Cancer Center, Santa Monica

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 oct 2026 · NCT07280013

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

Research Site, Duarte
Research Site, Irvine

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 oct 2026 · NCT06106945

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

UCLA Hematology/Oncology - Santa Monica, Los Angeles
University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 oct 2026 · NCT06615479

Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)

Berenson Cancer Center, Los Angeles

ReclutandoFase 4

Edades de 18 en adelante · Todos los sexos · Actualizado el 27 oct 2026 · NCT07609940

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

University of Southern California /ID# 272414, Los Angeles

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 27 oct 2026 · NCT06953960

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

City of Hope National Medical Center, Duarte
City of Hope Irvine Lennar, Irvine

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 26 oct 2026 · NCT04973605

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

UCSF Medical Center - Hematology and Blood and Marrow Transplant Clinic, San Francisco

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 22 oct 2026 · NCT05651932

Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study

City of Hope Medical Center, Duarte
City of Hope at Irvine Lennar, Irvine

ReclutandoFase 2

Edades de 60 en adelante · Todos los sexos · Actualizado el 22 oct 2026 · NCT06052826

A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

Research Site, Orange
Research Site, San Francisco
Research Site, Stanford

ReclutandoFase 3

Edades de 18 a 130 · Todos los sexos · Actualizado el 21 oct 2026 · NCT07735637

A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

City of Hope National Medical Center /ID# 280273, Duarte
City of Hope - Orange County Lennar Foundation Cancer Center /ID# 279067, Irvine

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 20 oct 2026 · NCT07409246

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

City of Hope National Medical Center /ID# 273132, Duarte
City of Hope - Orange County Lennar Foundation Cancer Center /ID# 277911, Irvine
University Of California, San Francisco /ID# 271662, San Francisco

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 19 oct 2026 · NCT06892522

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Cedars-Sinai Medical Center /ID# 278238, Los Angeles

ReclutandoFase 2/3

Edades de 18 en adelante · Todos los sexos · Actualizado el 19 oct 2026 · NCT07095452

Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment

City of Hope Comprehensive Cancer Center, Duarte

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 16 oct 2026 · NCT07463807

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

Research Site, Duarte

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 15 oct 2026 · NCT07681596

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

UC Irvine, Orange

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 14 oct 2026 · NCT07648264

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

Chao Family Comprehensive Cancer Center UCI, Orange

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 13 oct 2026 · NCT06980480

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

Research Site, La Jolla
Research Site, Los Angeles
Research Site, San Francisco

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 8 oct 2026 · NCT05850234

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

UCLA Hematology/Oncology - Westwood (Building 200 Suite 214), Los Angeles
UCSF Helen Diller Medical Center at Parnassus Heights, San Francisco

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 6 oct 2026 · NCT06297226

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

Research Site, Sacramento
Research Site, Santa Monica

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT07391657

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Beverly Hills Cancer Center Clinical Research Advisors LLC, Beverly Hills
UC Irvine Health Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
Valkyrie Clinical Trials, Los Angeles
y 1 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07518186

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

Research Site, Duarte

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07073547

A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

City of Hope - Duarte, Duarte
City of Hope - Lennar, Irvine

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07336472

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

University of California San Francisco, San Francisco

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06500884

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

UCSF, San Francisco

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT07116616

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Sutter Auburn, Auburn
Sutter Alta Bates, Berkeley
The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles
y 19 más

ReclutandoFase 2

Edades de 12 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT02693535

Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma

University of California, San Francisco, San Francisco

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 16 sept 2026 · NCT05892393

Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities

University of California Davis Comprehensive Cancer Center, Sacramento

ReclutandoEstudio observacional

Edades de 21 en adelante · Todos los sexos · Actualizado el 14 sept 2026 · NCT04314752

De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.